tiprankstipranks
Trending News
More News >
Shanghai Pharmaceuticals Holding Co Ltd Class H (HK:2607)
:2607
Advertisement

Shanghai Pharmaceuticals Holding Co (2607) Stock Statistics & Valuation Metrics

Compare
4 Followers

Total Valuation

Shanghai Pharmaceuticals Holding Co has a market cap or net worth of $66.94B. The enterprise value is HK$81.26B.
Market Cap$66.94B
Enterprise ValueHK$81.26B

Share Statistics

Shanghai Pharmaceuticals Holding Co has 919,072,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding919,072,700
Owned by Insiders
Owned by Institutions<0.01%

Financial Efficiency

Shanghai Pharmaceuticals Holding Co’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 4.47%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)4.47%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee5.57M
Profits Per Employee118.82K
Employee Count49,402
Asset Turnover1.24
Inventory Turnover6.28

Valuation Ratios

The current PE Ratio of Shanghai Pharmaceuticals Holding Co is 6.8. Shanghai Pharmaceuticals Holding Co’s PEG ratio is ―.
PE Ratio6.8
PS Ratio
PB Ratio
Price to Fair Value0.61
Price to FCF
Price to Operating Cash Flow9.81
PEG Ratio

Income Statement

In the last 12 months, Shanghai Pharmaceuticals Holding Co had revenue of 275.25B and earned 4.55B in profits. Earnings per share was 1.23.
Revenue275.25B
Gross Profit30.63B
Operating Income8.14B
Pretax Income8.02B
Net Income4.55B
EBITDA12.06B
Earnings Per Share (EPS)1.23

Cash Flow

In the last 12 months, operating cash flow was 989.26M and capital expenditures -1.12B, giving a free cash flow of 2.34B billion.
Operating Cash Flow989.26M
Free Cash Flow2.34B
Free Cash Flow per Share2.55

Dividends & Yields

Shanghai Pharmaceuticals Holding Co pays an annual dividend of HK$0.317, resulting in a dividend yield of 2.63%
Dividend Per ShareHK$0.317
Dividend Yield2.63%
Payout Ratio40.35%
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.74
52-Week Price Change21.34%
50-Day Moving Average12.32
200-Day Moving Average11.81
Relative Strength Index (RSI)38.75
Average Volume (3m)3.88M

Important Dates

Shanghai Pharmaceuticals Holding Co upcoming earnings date is Oct 24, 2025, TBA (Confirmed).
Last Earnings DateAug 28, 2025
Next Earnings DateOct 24, 2025
Ex-Dividend DateJul 16, 2025

Financial Position

Shanghai Pharmaceuticals Holding Co as a current ratio of 1.36, with Debt / Equity ratio of 68.88%
Current Ratio1.36
Quick Ratio1.05
Debt to Market Cap1.06
Net Debt to EBITDA1.00
Interest Coverage Ratio5.01

Taxes

In the past 12 months, Shanghai Pharmaceuticals Holding Co has paid 2.15B in taxes.
Income Tax2.15B
Effective Tax Rate0.27

Enterprise Valuation

Shanghai Pharmaceuticals Holding Co EV to EBITDA ratio is 4.64, with an EV/FCF ratio of 16.33.
EV to Sales0.20
EV to EBITDA4.64
EV to Free Cash Flow16.33
EV to Operating Cash Flow9.60

Balance Sheet

Shanghai Pharmaceuticals Holding Co has $47.50B in cash and marketable securities with $51.73B in debt, giving a net cash position of $4.23B billion.
Cash & Marketable Securities$47.50B
Total Debt$51.73B
Net Cash$4.23B
Net Cash Per Share$4.60
Tangible Book Value Per Share$18.02

Margins

Gross margin is 10.60%, with operating margin of 2.96%, and net profit margin of 1.65%.
Gross Margin10.60%
Operating Margin2.96%
Pretax Margin2.91%
Net Profit Margin1.65%
EBITDA Margin4.38%
EBIT Margin3.50%

Analyst Forecast

The average price target for Shanghai Pharmaceuticals Holding Co is $12.32, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$12.32
Price Target Upside2.10% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast3.60%
EPS Growth Forecast47.33%

Scores

Smart Score6
AI Score66.4
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis